OnKure Therapeutics announces it plans to submit IND applications to the FDA for its PI3Kα pan-mutant candidates OKI‑345 and OKI‑355 in the first half of 2027.
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | $50.00K | $37.00K |
| Gross Profit | N/A | N/A | N/A | $-50.00K | $-37.00K |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $54.39M | $36.93M | $29.77M | $39.77M | $19.52M |
| Operating Income | $-54.39M | $-36.93M | $-29.77M | $-39.82M | $-19.55M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income | $-52.67M | $-35.31M | $-29.51M | $-39.77M | $-19.46M |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-3.95 | $-2.65 | $-2.21 | $-21.92 | $-7.74 |
| EBITDA | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A |